--  Click here to launch the Post EASL 2008 Newsletter --

--  Click here to launch the Post EASL 2008 Slide Kit --

Learning Objectives
Identify key clinical factors which should be considered in the selection of the patient's initial antiretroviral treatment regimen.
Recognize and utilize strategies for managing the metabolic effects of antiretroviral therapy including dyslipidemia and insulin resistance, diabetes, and resultant cardiovascular risks.

Highlight the basic pharmacokinetic principles involved in the management of antiretroviral therapy, and how to appropriately manage HIV patients on antiretroviral therapy with attention to pharmacokinetics.


Supported by an Educational Grant from Tibotec Therapeutics

EASL
2008
Conference Coverage
Conference Coverage
 Google Custom Search
HIV and AIDS Top New Articles
Benefits of Adding Viral Load or CD4 Cell Count Monitoring to Clinical Monitoring Alone Are Modest
Does Tenofovir (Viread) Increase Liver Toxicity Related to Efavirenz (Sustiva)?
Body Fat and Blood Lipid Levels in Men and Women with HIV
Body Shape Changes in HIV Positive and HIV Negative Women
Hepatitis B and Hepatitis C
Top New Articles
EASL
2008

FibroScan Liver Stiffness Measurement Distinguishes Fast and Slow Fibrosis Patterns after Liver Transplantation

EASL
2008
Incidence of and Risk Factors for Hepatocellular Carcinoma in Hepatitis C Patients with Advanced Liver Disease: HALT-C Trial
EASL
2008
Sorafenib (Nexavar) Improves Outcomes in Patients with Hepatocellular Carcinoma
HIV-HCV and HIV-HBV Coinfection
Top New Article
Risk of Using Entecavir (Baraclude) without Concomitant Antiretroviral Therapy in HIV-HBV Coinfected Patients
Most Recent Conference Coverage
EASL 2008   April, 2008
CROI 2008   February, 2008
AASLD 2007   November, 2007

EACS 2007   October, 2007